Drug Safety Update

Subscribe to feed

Paracetamol and pregnancy - reminder that taking paracetamol during pregnancy remains safe

Patients should be reminded and reassured that there is no evidence that taking paracetamol during pregnancy causes autism in children. Paracetamol is recommended as the first-choice pain reliever for pregnant women, used at鈥�
- Therapeutic area: Anaesthesia and intensive care and 34 others
- Published: 23 September 2025
Abrysvo鈻� (Pfizer RSV vaccine) and Arexvy鈻� (GSK RSV vaccine): be alert to a small risk of Guillain-Barr茅 syndrome following vaccination in older adults

There is a small increase in the risk of Guillain-Barr茅 syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and Arexvy (GSK RSV vaccine) in adults aged 60 years and older. Healthca鈥�
- Therapeutic area: Anaesthesia and intensive care and 5 others
- Published: 7 July 2025
Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell鈻�): updated safety and educational materials to support patient discussion on reproductive risks

Updated safety and educational materials are now available to support the implementation of the regulatory measures announced in the November 2023 National Patient Safety Alert and the September 2024 Drug Safety Update. They鈥�
- Therapeutic area: General practice and 5 others
- Published: 10 June 2025
Kaftrio鈻� (Ivacaftor, tezacaftor, elexacaftor): risk of psychological side effects

Psychological side effects such as anxiety, low mood, sleep disturbance, poor concentration, and forgetfulness have been infrequently reported in people with cystic fibrosis treated with Kaftrio. Healthcare professionals sho鈥�
- Therapeutic area: General practice and 2 others
- Published: 7 May 2025
Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines

Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with or without anti-inflammatory maintenance therapy in patients with asthma. H鈥�
- Therapeutic area: General practice and 2 others
- Published: 24 April 2025
Fezolinetant鈻�(Veoza): risk of liver injury; new recommendations to minimise risk

Fezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. Liver function should be monitored before and during treatment in all patients ta鈥�
- Therapeutic area: Dispensing GP practices and 2 others
- Published: 10 April 2025

Help us improve 伊人直播

Don鈥檛 include personal or financial information like your National Insurance number or credit card details.

What were you doing?

What went wrong?

Help us improve 伊人直播

To help us improve 伊人直播, we鈥檇 like to know more about your visit today. .

伊人直播

6 updates

Therapeutic area

Published

6 updates

Is this page useful?

Help us improve 伊人直播

Help us improve 伊人直播

伊人直播

Cookies on 伊人直播

Drug Safety Update

Filter

6 updates

Therapeutic area

Published

6 updates

Is this page useful?

Help us improve 伊人直播

Help us improve 伊人直播